US 12,325,740 B2
Neutralizing anti-influenza B antibodies and uses thereof
Nicole Kallewaard-Lelay, Gaithersburg, MD (US); Qing Zhu, Gaithersburg, MD (US); Ebony Benjamin, Gaithersburg, MD (US); Leslie Wachter, Gaithersburg, MD (US); Andy Yuan, Monmouth, NJ (US); Josephine Mary McAuliffe, Gaithersburg, MD (US); Davide Corti, Bellinzona (CH); and Antonio Lanzavecchia, Bellinzona (CH)
Assigned to MEDIMMUNE, LLC, Gaithersburg, MD (US); and HUMABS BIOMED SA, Bellinzona (CH)
Filed by MEDIMMUNE, LLC, Gaithersburg, MD (US); and HUMABS BIOMED SA, Bellinzona (CH)
Filed on Sep. 8, 2023, as Appl. No. 18/463,736.
Application 17/499,495 is a division of application No. 16/676,974, filed on Nov. 7, 2019, granted, now 11,174,304, issued on Nov. 16, 2021.
Application 16/361,653 is a division of application No. 15/325,603, granted, now 10,294,292, issued on May 21, 2019, previously published as PCT/US2015/040385, filed on Jul. 14, 2015.
Application 18/463,736 is a continuation of application No. 17/499,495, filed on Oct. 12, 2021, granted, now 11,787,853.
Application 16/676,974 is a continuation of application No. 16/361,653, filed on Mar. 22, 2019, granted, now 10,519,221, issued on Dec. 31, 2019.
Claims priority of provisional application 62/024,804, filed on Jul. 15, 2014.
Prior Publication US 2024/0076357 A1, Mar. 7, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/10 (2006.01); A61P 31/16 (2006.01); G01N 33/569 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/1018 (2013.01) [A61P 31/16 (2018.01); G01N 33/56983 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/515 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/11 (2013.01); G01N 2469/10 (2013.01)] 16 Claims
 
1. An isolated antibody or an antigen binding fragment thereof that is capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages wherein the antibody or antigen binding fragment thereof includes a set of six CDRs: HCDR-1, HCDR-2, HCDR-3, LCDR-1, LCDR-2, LCDR-3, in which the set of six CDRs is HCDR-1 of SEQ ID NO.: 139, HCDR-2 of SEQ ID NO.: 140, HCDR-3 of SEQ ID NO.: 141, LCDR-1 of SEQ ID NO.: 142, LCDR-2 of SEQ ID NO.: 143 and LCDR-3 of SEQ ID NO.: 144;
wherein the isolated antibody or binding fragment thereof comprises a variant IgG Fc region; and
wherein the variant IgG Fc region comprises at least one substitution selected from 252Y, 254T and 256E as numbered by the EU index as set forth in Kabat.